|
-------- Original Message --------
| Subject:
|
ProMED: Salmonellosis, wild birds - USA |
| Date:
|
Sat, 18 Apr 2009 21:55:24 -0700 |
| From:
|
"Stephen M. Apatow"
<s.m.apatow@pathobiologics.org> |
| To:
|
ivphc.wg@pathobiologics.org |
18 April
2009
BTACC:
Pathobiologics
International
Dear Colleagues:
[Salmonellosis, wild birds - USA: (ID) 20090417.1456]
[ Salmonellosis, wild birds - USA (02): (NY) 20090418.1469]
These are very interesting discussions from an
epidemiological standpoint, because we are looking at geographic spread
via migratory birds and thresholds of clinically significant pathogens
as they relate to clinical manifestation.
As frequently noted by those who work in the Ag industrial complex,
Salmonella strains with virtually full antibiotic resistance are common
place. Those who have a grasp of this microbiological reality
understand the complexity of the picture.
[An international expert on the topic of Salmonellosis
is Anna Catharina Björnsdotter Berge, DVM, MPVM, PhD:
Pathobiologics International Consultancy
Referral. Papers: PubMed: Anna Catharina Berge]
The same is being said these days for challenges such as subclinical
MRSA (CDC: MRSA and the Workplace), widespread global human
exposure to H5N1 subclinical or atypical infections [Avian influenza, human (140): atypical infections"
20060905.2522] and subclinical infection of Ebola Reston in the mixing
vessel of pigs in the Philippines [Ebola-Reston,
porcine - Philippines (10): bat testing: 20090316.1075, Purdue research hints that birds could spread Ebola
virus, Purdue News, 12.16.2002].
These emerging infectious microbial challenges are important aspects of
the co-infection challenge in both veterinary and human public health.
At
Los Alamos (Future of Biodetection Systems: 2006), a key topic
discussed in the breakaway group led by Hong Cai and myself (Final Workshop Analysis: Pg. 11-13) , was the
importance of access to microarray capability, analysis of the sample
and accessible genomic level bioinformatics information broken down for
clinical interpretation.
A dilemma associated with this technological capability, is the number
of potential high consequence or drug resistant pathogens that could
exist in the clinical sample (drug resistant tuberculosis, salmonella,
H5N1/AI, etc., etc.) and interpretation of the data. Many believe
this represents
the next phase in the evolution of medicine.
Related:
- The Future of Biodetection Systems - Final Workshop
Analysis: The Future of Biodetection Systems Workshop was held
last year to bring together industry, academia, national labs, and
federal agency personnel in an interactive process, to develop a
roadmap for research and development investment in
biodetection. Sponsored by Los Alamos National
Laboratory, September 26 & 27 2006. -- Overview: BTACC Pathobiologics International.
Keynote: DNA-based Detection Technologies (Powerpoint):
Stephen M.Apatow, Humanitarian University Consortium Graduate
Studies Center , Veterinary for
Medicine Medicine and Law.
Stephen M. Apatow
Founder, Director of Research & Development
Humanitarian Resource Institute
Humanitarian University Consortium Graduate Studies
Center for Medicine, Veterinary Medicine & Law
Phone: 203-668-0282
Email: s.m.apatow@humanitarian.net
Internet: www.humanitarian.net
Pathobiologics International
Internet: www.pathobiologics.org
|
